Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Proliferative Vitreoretinopathy
Interventions: Adrenocorticotropic Hormone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
Interventions: Swept-Source (SS) OCT Angiography, Spectral-Domain (SD) OCT Angiography, Fundus Imaging, Axial Length Measurement Device; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy
Interventions: Topcon Camera, Optos Camera, Clarus Camera; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Age-Related Macular Degeneration, Eye Diseases
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose; Drug
Lead sponsor: Peter A Campochiaro, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-proliferative Diabetic Retinopathy
Interventions: OTX-TKI, Sham; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more

Conditions: Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
Interventions: OSDI questionnaire, SPEEDII questionnaire; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Uveitis, Macular Edema
Interventions: Efalizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inflammation
Interventions: Intravitreal Ketorolac; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dry Macular Degeneration
Interventions: SS-OCT imaging; Device
Lead sponsor: Boston Image Reading Center; Industry
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Neovascular Age-related Macular Degeneration, Macular Degeneration
Interventions: No Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Lucentis (Ranibizumab); Drug
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Choroideremia
Interventions: Vitamin A palmitate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 15 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5); Device
Lead sponsor: Notal Vision Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Bakersfield, California • Encino, California • Fullerton, California + 43 more

Conditions: Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, placebo, ranibizumab intravitreal injection; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Usher Syndrome, Cochlear Implantation
Interventions: Experimental manipulation of stimulation parameters; Other
Lead sponsor: Ohio State University; Other
Eligibility: 1 Year to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee

Conditions: Diabetic Retinopathy (DR)
Interventions: SaMD intended for the detection of diabetic retinopathy in adults with diabetes., An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.; Device
Lead sponsor: Digital Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: AEYE-DS Software; Device
Lead sponsor: AEYE Health Inc; Industry
Eligibility: 22 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Orlando, Florida • Jackson, Tennessee

Conditions: Gyrate Atrophy
Interventions: Gene therapy; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinitis Pigmentosa
Interventions: OCU400; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years to 99 Years
U.S. locations: 5
States / cities: Phoenix, Arizona • Deerfield Beach, Florida • Erie, Pennsylvania + 2 more

Conditions: Open-angle Glaucoma, Diabetic Retinopathy
Interventions: GlaucoHealth, GlaucoSelect, Placebo; Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Genetic Study of Age-Related Macular Degeneration

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Comparing 3 Imaging Systems

Blood and Saliva Sample Collection for AREDS 2

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections

Efalizumab to Treat Uveitis

Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

Non Exudative AMD Imaged With SS-OCT- Extension

Photodynamic Therapy for PDA in NV AMD

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Auditory Neural Function in Implanted Patients With Usher Syndrome

Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

Gene Therapy for Gyrate Atrophy

Expanded Access Program for RP in Adults

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy